Atricure, Inc. (ATRC) fundamentals score
Atricure is a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib or AF), left atrial appendage (LAA) management and post-operative pain management. Afib is an irregular heartbeat, or arrhythmia, which affects over 59 million people worldwide and is a growing epidemic.
Surgical & Medical Instruments & Apparatus · Healthcare · Listed on NASDAQ
Overall: 6.9 out of 10, Good long-term fundamentals
- Growth: 6.6/10
- Profitability: 6.5/10
- Financial health: 9.0/10
- Earnings quality: 8.2/10
- Valuation: 4.0/10
Scores are calculated from Atricure, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10